New research has found that Cannnabidiol is active against Gram-positive bacteria, including those responsible for many serious infections (such as Staphyloccocus aureus and Streptococcus pneumoniae), with potency similar to that of established antibiotics such as vancomycin or daptomycin.
The research is presented at ASM Microbe, the annual meeting of the American Society for Microbiology.
Cannabidiol, the main non-psychoactive chemical compound extracted from cannabis and hemp plants, has been approved by FDA for the treatment of a form of epilepsy, and is being investigated for a number of other medical conditions, including, anxiety, pain and inflammation. While there is limited data to suggest Cannabidiol can kill bacteria, the drug has not been thoroughly investigated for its potential as an antibiotic.
Work led by Dr Mark Blaskovich at The University of Queensland’s Institute for Molecular Bioscience’s Centre for Superbug Solutions, in collaboration with Botanix Pharmaceuticals Ltd, an early stage drug discovery company investigating topical uses of synthetic cannabidiol for a range of skin conditions, found that Cannabidiol was remarkably effective at killing a wide range of Gram-positive bacteria, including bacteria that have become resistant to other antibiotics, and did not lose effectiveness after extended treatment.
“Given cannabidiol’s documented anti-inflammatory effects, existing safety data in humans, and potential for varied delivery routes, it is a promising new antibiotic worth further investigation,” said Dr. Blaskovich. “The combination of inherent antimicrobial activity and potential to reduce damage caused by the inflammatory response to infections is particularly attractive.”
Importantly, the drug retained its activity against bacteria that have become highly resistant to other common antibiotics. Under extended exposure conditions that lead to resistance against vancomycin or daptomycin, Cannabidiol did not lose effectiveness. Cannabidiol was also effective at disrupting biofilms, a physical form of bacteria growth that leads to difficult-to-treat infections.
The project was co-funded by Botanix and Innovation Connections, an Australian government grant scheme to commercialize new products, processes and services. The paper will be presented on Sunday June 23rd from 11am-1 pm at the annual conference of the American Society for Microbiology, ASM Microbe 2019, at the Moscone Convention Center in San Francisco.
Learn more: Cannabidiol is a Powerful New Antibiotic
The Latest on: Cannnabidiol
The Latest on: Biomechanics
via Google News
The Latest on: Cannnabidiol
- County awards tax incentives to 161-job CBD manufacturer prospecton November 18, 2019 at 8:13 pm
SALISBURY — The Rowan County commissioners voted Monday to award tax incentives and other inducements to a cannabidiol (CBD) product manufacturing facility in northern Kannapolis that would create 161 ...
- CBD Across The Pond: Cannabidiol Use In Europeon November 18, 2019 at 4:06 pm
Receive the best hemp news in the industry delivered to your inbox every week! The post CBD Across The Pond: Cannabidiol Use In Europe appeared first on New Frontier Data. The preceding article is ...
- InnoCan Signs Agreement to Manufacture Products in the U.S.on November 18, 2019 at 4:04 pm
HERZELIYA, ISRAEL and CALGARY, ALBERTA / ACCESSWIRE / November 18, 2019 / InnoCan Pharma Corporation ("InnoCan" or the "Company") (CSE:INNO) announced today that it has signed an agreement with ...
- Here Are The CBD Products That Pass Our Toughest Scrutinyon November 18, 2019 at 12:31 pm
But as cannabis has become increasingly legalized and studied, this focus on potency has receded to make room for interest in things like terpenes and cannabidiol (CBD) content. In fact, people ...
- A guide to CBD topicals, balms, and lotionson November 18, 2019 at 10:32 am
However, before choosing one off the shelf or online, there are a few things to know first. CBD, or cannabidiol, is a compound produced by cannabis and hemp plants. Unlike THC, CBD doesn’t produce a ...
- Main Line pharma firm awarded patent for cannabidiol treatmenton November 13, 2019 at 11:18 am
The U.S. Patent and Trademark Office has issued a patent to Zynerba Pharmaceuticals for the company’s lead new drug candidate, a synthetic cannabidiol medicine. The patent, which expires in 2038, ...
- Howard Center presents an overview of cannabidiol (CBD) at community education sessionon November 12, 2019 at 9:49 am
Burlington, VT—Howard Center will present An Overview of Cannabidiol (CBD) – Magic Elixir or Not? as part of their Fall Community Education Series on Wednesday, November 13 at Dealer.com. The session ...
- Insights on the effects of cannabidiol on severe form of epilepsyon November 10, 2019 at 12:58 pm
New results may help explain why cannabidiol -- a chemical component of marijuana with no psychoactive properties -- reduces the frequency of seizures in patients with a severe form of epilepsy.
- How Cannabidiol is Driving Change in Making Pet Treatson November 9, 2019 at 5:57 am
Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider ...
- Study provides insights on the effects of cannabidiol on severe form of epilepsyon November 7, 2019 at 1:31 pm
Results from a study published in the British Journal of Clinical Pharmacology may help explain why cannabidiol—a chemical component of marijuana with no psychoactive properties—reduces the frequency ...
via Bing News